<DOC>
	<DOCNO>NCT00164112</DOCNO>
	<brief_summary>Studies previously show broad drug interaction screen perform use enzyme specific probe oral caffeine CYP1A2 , N-acetyltrasferase-2 ( NAT-2 ) , xanthine oxidase ( XO ) , warfarin plus vitamin K CYP2C9 , omeprazole CYP 2C19 , dextromethorphan CYP2D6 , midazolam CYP3A4/5 . This combination probe validate Cooperstown 5+1 Cocktail ( 5+1 ) .1 The use 5+1 cocktail provide information drug metabolizing enzyme metabolize 90 % hepatically eliminate drug fraction cost individual study . Using cocktail biomarkers reduce overall cost drug interaction screening . The purpose study evaluate effect three Food Drug Administration ( FDA ) approve oral antibiotic ( azithromycin , telithromycin , levofloxacin ) metabolism medication take together . This determine measuring activity drug metabolize enzyme follow administration certain drug probe ( caffeine , dextromethorphan , omeprazole , midazolam , warfarin vitamin K ) . A total 16 subject complete four phase study : 1 ) Cooperstown 5+1 alone , 2 ) Azithromycin plus Cooperstown 5+1 , 3 ) Telithromycin plus Cooperstown 5+1 , 4 ) Levofloxacin plus Cooperstown 5+1 .</brief_summary>
	<brief_title>Comparative Effects Azithromycin , Telithromycin Levofloxacin Drug Metabolizing Enzymes</brief_title>
	<detailed_description>Specific Aims 1 . What purpose study ? What question design answer ? To compare effect azithromycin , telithromycin , levofloxacin activity 7 hepatic drug metabolize enzyme use Cooperstown 5+1 Cocktail . Background 2 . Why study important ? We previously show broad drug interaction screen perform use enzyme specific probe oral caffeine CYP1A2 , N-acetyltrasferase-2 ( NAT-2 ) , xanthine oxidase ( XO ) , warfarin plus vitamin K CYP2C9 , omeprazole CYP 2C19 , dextromethorphan CYP2D6 , midazolam CYP3A4/5 . This combination probe validate Cooperstown 5+1 Cocktail ( 5+1 ) .1 The use 5+1 cocktail provide information drug metabolizing enzyme metabolize 90 % hepatically eliminate drug fraction cost individual study . Using cocktail biomarkers reduce overall cost drug interaction screening . The FDA indicate use probe drug do place specific drug interaction studies.2 This streamline detection drug interaction reduce cost . However , important control genetic polymorphism drug interaction trial genetic makeup affect outcome . Experimental Design Methods 3 ) Describe detail experimental design methodology . What information collect collect ? Provide description subject ’ participation start finish . Prior procedure study subject provide write informed consent . All subject genotyped CYP2D6 , CYP2C9 , CYP2C19 obtain informed consent pharmacogenomics . This distinguish poor metabolizers extensive metabolizers . Prestudy screen conduct within 4 week first study phase . Subjects undergo complete medical history , social history ( include medication , alcohol , tobacco use ) , physical examination , standard 12-lead electrocardiogram ( ECG ) , laboratory screening assure inclusion exclusion criterion meet . The laboratory screen data obtain : complete blood count , prothrombin time ( PT ) , international normalize ratio ( INR ) , macroscopic microscopic urinalysis , electrolytes , blood urea nitrogen ( BUN ) , serum creatinine , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , total bilirubin , serum albumin . Women childbearing potential ( defined premenopausal history hysterectomy tubal ligation ) undergo serum pregnancy test screen visit urine pregnancy test prior phase study . Following enrollment , subject participate 4 study phase random order . Study Design Procedures This randomize , crossover , open-label study . Prestudy screen conduct within 4 week first study phase . Screening visit involve obtain inform consent , medical history , social history , physical examination , ECG , laboratory test . Following enrollment , subject randomize ( cross ) 4 phase describe Table 1 . Table 1 . Study Design Study Drugs Procedure Phase 1 ( control ) Cooperstown 5+1 Cocktail alone . The Cooperstown 5+1 Cocktail consist follow component : 1 . Caffeine ( 2 mg/kg orally , round near 50 mg ) collection 12-hour urine . 2 . Warfarin ( 10 mg + 10 mg vitamin K orally ) collection plasma 96 hour . Plasma collection time 0 , 3 , 6 , 12 , 24 , 36 , 48 , 72 96 hour dose . The INR check 48 hour . If INR &gt; 1.7 , 5 mg vitamin K administer mouth daily INR 1.2 . 3 . Omeprazole ( 40 mg orally ) collection plasma sample 2 hour dose . 4 . Dextromethorphan ( 30 mg orally ) collection 12-hour urine . 5 . Midazolam ( 0.075 mg/kg orally ) collection 8 plasma sample 6 hour ( Phase 1 ) determine CYP3A activity ( MDZ CL/F mL/min ) . Samples draw immediately midazolam administration ( 0 minute ) , 5 minute , 0.5 , 1 , 2 , 4 , 5 6 hour . Breathing , heart rate , oxygen saturation monitor via pulse oximetry first 90 minute midazolam dose . Phase 2 Azithromycin 500 mg qAM 3 day empty stomach . On day 4 , Cooperstown 5+1 Cocktail administer fourth dose azithromycin give 2 hour 5+1 administration . Phase 3 Telithromycin 800 mg qAM 3 day empty stomach . On day 4 , Cooperstown 5+1 Cocktail administer fourth dose telithromycin give 2 hour 5+1 administration . Phase 4 Levofloxacin 750 mg qAM 3 day empty stomach . On day 4 , Cooperstown 5+1 Cocktail administer fourth dose levofloxacin give 2 hour 5+1 administration . During azithromycin , telithromycin , levofloxacin phase , plasma sample midazolam collect 0.25 , 0.75 , 1 , 1.5 , 2 , 4 , 6 , 8 , 10 , 12 , 24 hour allow adequate sampling drug potentially inhibit CYP3A . The 5+1 cocktail administer day 4 minimum 8-hour fasting . Subjects allow eat 2 hour administration study drug ( 5+1 cocktail antibiotic ) . Washout period : One week phase except azithromycin phase require ensure drug completely eliminate body . Three week azithromycin phase require since azithromycin longer half-life . Sample Collection Analysis • For caffeine phenotyping , subject collect urine 12 hour receive dose determine CYP1A2 activity [ ( AFMU+1X+1U ) /17U ] , NAT-2 [ AFMU/ ( AFMU+1X+1U ) ] , XO [ 1U/ ( 1X+1U ) ] . Urine acidify ascorbic acid ( vitro ) prevent AFMU conversion . • For warfarin phenotyping , blood sample obtain 0 , 3 , 6 , 12 , 24 , 36 , 48 , 72 96 hour follow warfarin plus vitamin K administration determine CYP2C9 activity ( S-warfarin CL/F , mL/min ) . For first 12 hour , blood obtain intravenous ( IV ) catheter . Thereafter via venipuncture . • For omeprazole phenotyping , one 15 mL blood sample draw 2 hour oral omeprazole dose determine CYP2C19 activity ( OMP/5OH OMP ) . • For dextromethorphan phenotyping , subject collect urine 12 hour receive dose determine CYP2D6 activity ( DM/DX ) . - For midazolam phenotyping , use oral midazolam give assessment inhibition gut hepatic CYP3A . - For Phase 1 ( 5+1 cocktail alone ) , 8 blood sample ( 10 mL ) obtain immediately midazolam administration ( 0 minute ) , 5 minute , 0.5 , 1 , 2 , 4 , 5 6 hour determine CYP3A activity ( MDZ CL/F , mL/min ) . - During azithromycin , telithromycin , levofloxacin phase , blood sample collect 0.25 , 0.75 , 1 , 1.5 , 2 , 4 , 6 , 8 , 10 , 12 , 24 hour ( allow adequate sample drug potentially inhibit CYP3A ) . - All blood sample ( except 15 mL omeprazole ) collect duplicate 10 mL EDTA-containing test tube centrifuge 15 minute 2800 rpm . - Plasma urine sample freeze -80C analysis . Data Analysis • Caffeine phenotyping assay : Urine aliquot assay determine urinary concentration 1U , 1X , 17U , AFMU . Urine aliquot analyze University Missouri , Kansas City . Caffeine demethylation ratio use express CYP1A2 , NAT-2 , XO activity . • S- R-warfarin phenotyping assay : S- R-warfarin plasma determine utilizing high performance liquid chromatography ( HPLC ) analysis University North Carolina , Chapel Hill . Warfarin clearance determine use non-compartmental analysis . WinNonlin® 3.1 use pharmacokinetic analysis . • Omeprazole phenotyping assay : Blood sample analyze University North Carolina , Chapel Hill , determine plasma concentration OMP 5OH OMP . The ratio OMP 5OH OMP 2 hour follow oral dose omeprazole use describe CYP2C19 activity . • Dextromethorphan phenotyping assay : Urine aliquot analyze University Missouri , Kansas City , determine urinary concentration DM/DX . The dextromethorphan metabolic ratio use describe CYP2D6 activity . • Midazolam phenotyping assay : Blood sample analyze determine plasma concentration midazolam , 1-hydroxymidazolam , 4-hydroxymidazolam . Analyses perform Oneida Research Services , Inc. use proprietary LC/MS/MS method . Midazolam clearance use reflect CYP3A activity clearance determine use non-compartmental analysis midazolam plasma concentration-time data . WinNonlin® 3.1 use pharmacokinetic analysis . Statistical Analysis - Sample size : Using =0.05 , four treatment phase , =0.20 ( power 80 % ) , estimate sample size sixteen volunteer detect 25 % difference metabolism . - Data analyze use FDA ’ standard bioequivalency testing.3 If drug phase fall outside 0.8-1.25 range versus control phase , BE show . 4 ) If research part treatment protocol , identify part routine part do solely research . This study research purpose .</detailed_description>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Telithromycin</mesh_term>
	<criteria>Healthy adult age 18 55 year . Ability provide write informed consent . Willing avoid medication ( study drug ) may inhibit induce hepatic microsomal enzyme study period . This include prescription nonprescription medication , vitamin , herbal supplement , nutriceuticals . Willing avoid drinking equivalence one beer per day ( one 12 ounce beer equivalent alcohol intake ) throughout study period . Women childbearing potential willing practice nonhormonal method contraception study phase . Willing adhere dietary restriction require study . Clinically significant abnormal finding history , physical exam , ECG , laboratory testing . Elevated liver function test twice upper limit normal range ( male AST 050 U/L , ALT 060 U/L , GGT 1150 ; female AST 040 U/L , ALT 050 U/L , GGT 732 ) , total bilirubin &gt; 1.3mg/dL . Baseline INR &gt; 1.2 . Serum creatinine normal range Women pregnant , breastfeeding , and/or use acceptable form nonhormonal contraception ( barrier method abstinence ) study . History gastrointestinal bleeding peptic ulcer disease . Any condition may affect drug absorption ( e.g. , gastrectomy , malabsorption syndrome ) . History known hypersensitivity serious adverse reaction azithromycin , telithromycin , levofloxacin , midazolam , dextromethorphan , caffeine , omeprazole , heparin , warfarin , vitamin K. Poor IV access determine investigator . Current illicit drug use . History tobacco use within 3 month screen . Use drug know inhibit induce hepatic enzyme within 30 day first study phase . Regular alcohol intake exceed 1 drink/day ( 1 drink = 5 ounce wine 12 ounce beer 1 ounce hard liquor ) within 1 month screen . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study drug . Presence condition investigator feel would interfere successful completion study . Poor metabolizers CYP2D6 , CYP2C9 , CYP2C19 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>Cooperstown Cocktail</keyword>
	<keyword>Drug Metabolizing Enzymes</keyword>
	<keyword>Drug Interactions</keyword>
	<keyword>Phenotyping</keyword>
</DOC>